Determination of serotyping antigens, Clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009 to 2013

Journal of Medical Microbiology

Volumn 63, Issue , 2014, Pages 1490-1499

  Law, Dennis K S ^a   Zhou, Jianwei ^a   Deng, Saul ^a   Hoang, Linda ^b   Tyrrell, Gregory ^c   Horsman, Greg ^d   Wylie, John ^c   Tsang, Raymond S W ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b BCCDC Public Health Microbiology and Reference Laboratory   (Canada)

^c PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^d Saskatchewan Disease Control Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; MENINGOCOCCUS VACCINE; 4CMENB VACCINE; PORIN; PORIN PROTEIN, NEISSERIA;

ARTICLE; BACTERIUM ISOLATE; BLOOD GROUP TYPING; CANADA; DNA SEQUENCE; GENE INSERTION SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; MENINGOCOCCOSIS; MOLECULAR CLONING; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; SEROTYPE; SEROTYPING; STOP CODON; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; HUMAN; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANTIGENS, BACTERIAL; CANADA; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PORINS; SEROTYPING;

EID: 84908312876     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.079921-0     Document Type: Article

References (45)

1. Abdillahi, H. & Poolman, J. T. (1987). Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 48, 367–371.
2. Ashton, F. E. & Caugant, D. A. (2001). The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. Can J Microbiol 47, 283–289.
3. Ashton, F. E., Ryan, J. A., Borczyk, A., Caugant, D. A., Mancino, L. & Huang, D. (1991). Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 29, 2489–2493.
4. Bambini, S., Muzzi, A., Olcen, P., Rappuoli, R., Pizza, M. & Comanducci, M. (2009). Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27, 2794–2803.
5. Bennett, D. E., Mulhall, R. M. & Cafferkey, M. T. (2004). PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z. J Clin Microbiol 42, 1764–1765.
6. Bettinger, J. A., Scheifele, D. W., Halperin, S. A., Vaudry, W., Findlow, J., Borrow, R., Medini, D., Tsang, R. & members of the Canadian Immunization Monitoring Program, Active (IMPACT) (2013a). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 32, 124–130.
7. Bettinger, J. A., Deeks, S. L., Halperin, S. A., Tsang, R. & Scheifele, D. W. (2013b). Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 12, 505–517.
8. Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, O., Fredriksen, J. H., Halstensen, A., Holten, E., Lindbak, A. K., Nøkleby, H. & other authors (1991). Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093–1096.
9. Borrow, R., Claus, H., Guiver, M., Smart, L., Jones, D. M., Kaczmarski, E. B., Frosch, M. & Fox, A. J. (1997). Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol Infect 118, 111–117.
10. Borrow, R., Claus, H., Chaudhry, U., Guiver, M., Kaczmarski, E. B., Frosch, M. & Fox, A. J. (1998). siaD PCR ELISA for confirmation and identification of serogroup Y and W135 meningococcal infections. FEMS Microbiol Lett 159, 209–214.
11. Clarke, S. C., Diggle, M. A., Mölling, P., Unemo, M. & Olcén, P. (2003). Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Vaccine 21, 2468–2473.
12. Claus, H., Maiden, M. C. J., Maag, R., Frosch, M. & Vogel, U. (2002). Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148, 1813–1819.
13. Comanducci, M., Bambini, S., Brunelli, B., Adu-Bobie, J., Aricò, B., Capecchi, B., Giuliani, M. M., Masignani, V., Santini, L. & other authors (2002). NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195, 1445–1454.
14. Dang, V., Jamieson, F. B., Wilson, S., Rawte, P., Crowcroft, N. S., Johnson, K., Tsang, R. S. W. & Deeks, S. L. (2012). Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 12, 202.
15. de Filippis, I., Gopalan, V. & Huyen, Y. (2011). PorA VR3 Typing Database: a web-based resource for the determination of PorA VR3 alleles of Neisseria meningitidis. Infect Genet Evol 11, 248–249.
16. de Moraes, J. C., Perkins, B. A., Camargo, M. C., Hidalgo, N. T., Barbosa, H. A., Sacchi, C. T., Landgraf, I. M., Gattas, V. L., Vasconcelos, H. G. & other authors (1992). Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074–1078.
17. Finne, J., Leinonen, M. & Mäkelä, P. H. (1983). Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 322, 355–357.
18. Gilca, R., Deceuninck, G., Lefebvre, B., Tsang, R., Amini, R., Gilca, V., Douville-Fradet, M., Markowski, F. & De Wals, P. (2012). The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS ONE 7, e50659.
19. Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A. & other authors (2006). A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103, 10834–10839.
20. Granoff, D. M. (2010). Review of meningococcal group B vaccines. Clin Infect Dis 50 (Suppl 2), S54–S65.
21. Hoang, L. M. N., Thomas, E., Tyler, S., Pollard, A. J., Stephens, G., Gustafson, L., McNabb, A., Pocock, I., Tsang, R. & Tan, R. (2005). Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 40, e38–e42.
22. Jamieson, F. B., Rawte, P., Deeks, S. L., Zhou, J., Law, D. K. S., Deng, S. & Tsang, R. S. W. (2013). Genetic and antigenic characterization of invasive endemic serogroup B Neisseria meningitidis from Ontario, Canada, in 2001-2010. J Med Microbiol 62, 46–55.
23. Johswich, K. O., Zhou, J., Law, D. K. S., St Michael, F., McCaw, S. E., Jamieson, F. B., Cox, A. D., Tsang, R. S. W. & Gray-Owen, S. D. (2012). Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis. Infect Immun 80, 2346–2353.
24. Law, D. K. S., Lorange, M., Ringuette, L., Dion, R., Giguère, M., Henderson, A. M., Stoltz, J., Zollinger, W. D., De Wals, P. & Tsang, R. S. W. (2006). Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 44, 2743–2749.
25. Lewis, S., Sadarangani, M., Hoe, J. C. & Pollard, A. J. (2009). Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev Vaccines 8, 729–745.
26. Lucidarme, J., Comanducci, M., Findlow, J., Gray, S. J., Kaczmarski, E. B., Guiver, M., Vallely, P. J., Oster, P., Pizza, M. & other authors (2010). Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 17, 919–929.
27. Lucidarme, J., Tan, L., Exley, R. M., Findlow, J., Borrow, R. & Tang, C. M. (2011). Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 18, 1002–1014.
28. Maiden, M. C. J., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Urwin, R., Zhang, Q., Zhou, J., Zurth, K. & other authors (1998). Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95, 3140–3145.
29. Masignani, V., Comanducci, M., Giuliani, M. M., Bambini, S., Adu- Bobie, J., Arico, B., Brunelli, B., Pieri, A., Santini, L. & other authors (2003). Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197, 789–799.
30. Miller, E., Salisbury, D. & Ramsay, M. (2001). Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (Suppl 1), S58–S67.
31. Murphy, E., Andrew, L., Lee, K. L., Dilts, D. A., Nunez, L., Fink, P. S., Ambrose, K., Borrow, R., Findlow, J. & other authors (2009). Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200, 379–389.
32. Oster, P., Lennon, D., O’Hallahan, J., Mulholland, K., Reid, S. & Martin, D. (2005). MeNZB: a safe and highly immunogenic tailormade vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191–2196.
33. Richmond, P. C., Marshall, H. S., Nissen, M. D., Jiang, Q., Jansen, K. U., Garcés-Sánchez, M., Martinón-Torres, F., Beeslaar, J., Szenborn, L. & other authors (2012). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, singleblind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12, 597–607.
34. Riou, J. Y. & Guibourdenche, M. (1992). Laboratory Methods, Neisseria and Branhamella. Paris, France: Institut Pasteur.
35. Sacchi, C. T., Lemos, A. P., Brandt, M. E., Whitney, A. M., Melles, C. E. A., Solari, C. A., Frasch, C. E. & Mayer, L. W. (1998). Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5, 845–855.
36. Santolaya, M. E., O’Ryan, M. L., Valenzuela, M. T., Prado, V., Vergara, R., Muñoz, A., Toneatto, D., Graña, G., Wang, H. & other authors (2012). Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379, 617–624.
37. Shao, Z., Li, W., Ren, J., Liang, X., Xu, L., Diao, B., Li, M., Lu, M., Ren, H. & other authors (2006). Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 367, 419–423.
38. Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R. & Terry, M. H. (1991). Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14, 195–207, discussion 208–210.
39. Taha, M. K. (2000). Simultaneous approach for nonculture PCRbased identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 38, 855–857.
40. Tsang, R. S. W., Henderson, A. M., Cameron, M. L., Tyler, S. D., Tyson, S., Law, D. K. S., Stoltz, J. & Zollinger, W. D. (2007). Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 45, 1753–1758.
41. Vedros, N. A. (1987). Development of meningococcal serogroups. In Evolution of Meningococcal Disease, pp. 33–37.
42. Edited by N. A. Vedros. Boca Raton, FL.: CRC Press. Wang, X., Cohn, A., Comanducci, M., Andrew, L., Zhao, X., MacNeil, J. R., Schmink, S., Muzzi, A., Bambini, S. & other authors (2011). Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29, 4739–4744.
43. Warshawsky, B., Desai, S. & Langley, J. (2009). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 36, 1–40.
44. Xie, O., Pollard, A. J., Mueller, J. E. & Norheim, G. (2013). Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 31, 2852–2861.
45. Zhou, J., Lefebvre, B., Deng, S., Gilca, R., Deceuninck, G., Law, D. K. S., De Wals, P. & Tsang, R. S. W. (2012). Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST- 269 clone since it first emerged in 2003. J Clin Microbiol 50, 1545–1551.